Unavailable
Unavailable
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/18/2024 | Buy → Hold | Needham | |
5/30/2024 | $90.00 | Buy | Goldman |
2/1/2024 | $65.00 → $80.00 | Neutral → Buy | Mizuho |
7/19/2023 | $59.00 | Outperform | Robert W. Baird |
6/30/2023 | $64.00 | Buy | CL King |
5/30/2023 | $58.00 | Overweight | Morgan Stanley |
3/29/2023 | $57.00 | Buy | UBS |
12/22/2022 | $52.00 | Neutral | Mizuho |
SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)
SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)
SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)
Acquisition to complement electrophysiology portfolio with solution to advance the treatment of complex atrial fibrillation MARLBOROUGH, Mass., Nov. 4, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced it has entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company. Cortex is a privately held medical technology company focused on the development of a diagnostic mapping solution which may identify triggers and drivers outside of the pulmonary veins that are foundational to atrial fibrillation (AF), a heart rhythm disorder affecting nearly 38 million people globally.1
MARLBOROUGH, Mass. and WASHINGTON, Oct. 30, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced the results of the primary endpoint of the ACURATE IDE clinical trial, which evaluated the ACURATE neo2™ Aortic Valve System in the treatment of patients with severe, symptomatic aortic stenosis at low, intermediate, high and extreme risk of open-heart surgery. The data were presented as a late-breaking clinical trial at Transcatheter Cardiovascular Therapeutics® (TCT®) 2024, the annual scientific symposium of the Cardiovascular Research Foundation® (CRF®).
MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.
10-Q - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
10-Q - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.
-Company to also host virtual webcast with a cardiology business update- MARLBOROUGH, Mass., Oct. 2, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2024, on Wednesday, October 23, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the third quarter on October 23 prior to the conference call.
MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $324 million or $0.22 per share (EPS), compared to $261 million or $0.18 per share a year ago, and achieved adjusted3 EPS of $0.62 for the period, compared to $0.53 a year ago.
For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide
WOONSOCKET, R.I., Sept. 21, 2023 /PRNewswire/ -- CVS Health Corporation (NYSE:CVS) has appointed Michael F. Mahoney, Chairman and CEO of Boston Scientific Corporation (NYSE:BSX), a global medical technology leader, to serve on the Board of Directors (the "Board") of CVS Health, effective November 1. "Mike's focus throughout his career – to drive improvements in health outcomes and increase access to care – align with our mission at CVS Health," said CVS Health President and CEO Karen S. Lynch. "Adding a well-respected health care leader to our Board demonstrates our continued
Nordson Corporation (NASDAQ:NDSN) announced the appointment of Dr. Milton Morris, recently retired president and chief executive officer of Neuspera Medical, Inc., to its board of directors. Dr. Morris will bring robust business leadership experience, as well as a legacy of successful product innovation, to the board. "We are pleased to welcome Milton as a new independent director. His passion for innovation and new product development aligns well with Nordson's strength of understanding customer needs and bringing diversified precision technology solutions to market. In addition, his professional background in medical devices will enhance our understanding, as Nordson plans to further exp
Westport, CT, Sept. 21, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the appointment of James J. Barry, Ph.D. as an Independent Director to its Board of Directors. Dr. Barry has more than 30 years of experience in the medical device industry as an executive and corporate board director. He is currently the Principal Owner at Convergent Biomedical Group LLC., a company providing advisory services to the life sciences industry. Prior to Conver
4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
Needham downgraded Boston Scientific from Buy to Hold
Goldman initiated coverage of Boston Scientific with a rating of Buy and set a new price target of $90.00
Mizuho upgraded Boston Scientific from Neutral to Buy and set a new price target of $80.00 from $65.00 previously
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird increased Apple Inc. (NASDAQ:AAPL) price target from $200 to $240. Baird analyst William Power maintained an Outperform rating. Apple shares fell 0.1% to trade at $218.51 on Thursday. See how other analysts view this stock. Truist Securities raised the price target for ServiceNow, Inc. (NYSE:NOW) from $750 to $780. Truist Securities analyst Joel Fishbein maintained a Hold rating. ServiceNow shares gained 11.9% to trade at $817.75 on Thursday. See how other analysts view this stock. JP Morg
JP Morgan analyst Robbie Marcus maintains Boston Scientific (NYSE:BSX) with a Overweight and raises the price target from $82 to $85.
Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and raises the price target from $83 to $88.